Dias Da Silva Magnus R, Cerutti Janete M, Arnaldi Liliane A T, Maciel Rui M B
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo 781, 04039-032 São Paulo, SP, Brazil.
J Clin Endocrinol Metab. 2002 Nov;87(11):4881-4. doi: 10.1210/jc.2002-020698.
Hypokalemic Periodic Paralyses comprise diverse diseases characterized by acute and reversible attacks of severe muscle weakness, associated with low serum potassium. The most common causes are Familial Hypokalemic Periodic Paralysis (FHypoKPP), an autosomal dominant disease, and Thyrotoxic Hypokalemic Periodic Paralysis (THypoKPP), secondary to thyrotoxicosis. Symptoms of paralysis are similar in both diseases, distinguished by thyrotoxicosis present in THypoKPP. FHypoKPP is caused by mutations in ionic channel genes calcium (CACN1AS), sodium (SCN4A) and potassium (KCNE3). Since both diseases are similar, we tested the hypothesis that THypoKPP could carry the same mutations described in FHypoKPP, being the paralysis a genetically conditioned complication of thyrotoxicosis. In 15 patients with THypoKPP, using target-exon PCR, CSGE screening, and direct sequencing, we excluded known mutations in CACN1AS and SCN4A genes. On the other hand, we were able to identify the R83H mutation in the KCNE3 gene in one sporadic case of THypoKPP, a man who had been asymptomatic until developing thyrotoxicosis caused by Graves' disease; we confirmed the disease-causing mutation in 2 of 3 descendants. R83H was recently found in two FHypoKPP unrelated families, in which the mutant decreased outward potassium flux, resulting in a more positive resting membrane potential. We, therefore, identified the first genetic defect in THypoKPP, a mutation in the KCNE3 gene.
低钾性周期性麻痹包括多种疾病,其特征为严重肌无力的急性可逆性发作,并伴有血清钾降低。最常见的病因是家族性低钾性周期性麻痹(FHypoKPP),一种常染色体显性疾病,以及继发于甲状腺毒症的甲状腺毒性低钾性周期性麻痹(THypoKPP)。两种疾病的麻痹症状相似,区别在于THypoKPP存在甲状腺毒症。FHypoKPP由离子通道基因钙(CACN1AS)、钠(SCN4A)和钾(KCNE3)的突变引起。由于两种疾病相似,我们检验了这样一个假设,即THypoKPP可能携带FHypoKPP中描述的相同突变,麻痹是甲状腺毒症的一种遗传条件性并发症。在15例THypoKPP患者中,我们使用靶向外显子PCR、CSGE筛查和直接测序,排除了CACN1AS和SCN4A基因中的已知突变。另一方面,我们在1例散发性THypoKPP病例中鉴定出KCNE3基因中的R83H突变,该男子在因格雷夫斯病导致甲状腺毒症之前一直无症状;我们在3个后代中的2个中证实了致病突变。最近在2个不相关的FHypoKPP家族中发现了R83H,其中突变体减少了外向钾通量,导致静息膜电位更正。因此,我们鉴定出了THypoKPP中的首个遗传缺陷,即KCNE3基因中的一个突变。